We are live on ! Find out more
EPRX

Eupraxia Pharmaceuticals
EPRX

54 hedge funds and large institutions have $157M invested in Eupraxia Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

633% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 3

217% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 6

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

54% more funds holding

Funds holding: 35 → 54 (+19)

51% more capital invested

Capital invested by funds: $104M → $157M (+$53.2M)

9.29% more ownership

Funds ownership: 27.31% → 36.59% (+9.3%)

Holders
54
Holders Change
+19
Holders Change %
+54.29%
% of All Funds
0.66%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
22
Increased
19
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AAA
Affinity Asset Advisors
New York
+$10.4M
2
RG
Redmile Group
California
+$5.63M
3
RCMNY
Rubric Capital Management (New York)
New York
+$5.56M
4
Ameriprise
Ameriprise
Minnesota
+$5.22M
5
IC
Ikarian Capital
Texas
+$4.87M

Top Sellers

Rank Fund Capital Flow
1
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$2.09M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$500K
3
BGC
Beutel, Goodman & Co
Ontario, Canada
-$345K
4
QC
Quadrature Capital
United Kingdom
-$326K
5
XT
XTX Topco
Cayman Islands
-$122K
Name Holding Trade Value Shares
Change 		Change in
Stake
BGC
1
Beutel, Goodman & Co
Ontario, Canada
$26.4M -$345K -42,908 -1%
AAA
2
Affinity Asset Advisors
New York
$11.5M +$10.4M +1,289,005 +430%
Balyasny Asset Management
3
Balyasny Asset Management
Illinois
$9.77M – – –
VC
4
Vivo Capital
California
$9.77M – – –
IC
5
Ikarian Capital
Texas
$8.79M +$4.87M +604,741 +99%
GPP
6
Great Point Partners
Connecticut
$8.69M – – –
SC
7
Scotia Capital
Ontario, Canada
$7.24M +$451K +55,995 +4%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$7.01M +$2.06M +255,471 +36%
UBS Group
9
UBS Group
Switzerland
$5.52M +$4.37M +542,611 +247%
RG
10
Redmile Group
California
$5.07M +$5.63M +700,000 New
RCMNY
11
Rubric Capital Management (New York)
New York
$5M +$5.56M +691,170 New
SCM
12
Squadron Capital Management
Illinois
$4.92M +$1.45M +180,000 +36%
ABG
13
Ally Bridge Group
New York
$4.78M +$2.11M +262,480 +66%
Ameriprise
14
Ameriprise
Minnesota
$4.7M +$5.22M +649,074 New
PHS
15
PFM Health Sciences
California
$3.92M +$4.35M +540,871 New
WP
16
Woodline Partners
California
$3.19M +$3.55M +440,551 New
SFCM
17
Seven Fleet Capital Management
California
$3.14M +$3.49M +433,515 New
Alyeska Investment Group
18
Alyeska Investment Group
Illinois
$2.71M +$3.02M +375,000 New
VCIM
19
Velan Capital Investment Management
Georgia
$2.55M – – –
SC
20
SummitTX Capital
Texas
$2.37M +$1.22M +152,049 +86%
ACM
21
Aisling Capital Management
New York
$2.35M +$2.62M +325,000 New
BFM
22
Boothbay Fund Management
New York
$2.34M +$1.35M +167,512 +107%
DT
23
DV Trading
Illinois
$2M +$2.22M +276,000 New
Bank of America
24
Bank of America
North Carolina
$1.94M +$120K +14,900 +6%
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$1.89M +$524K +65,099 +33%
1
2 3

EPRX Hedge Fund Activity: Q1 2026 in Review

54 of the 8,137 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q1 2026, worth a combined $157M — up 51% from $104M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new EPRX positions and 3 closed out — a net gain of 19 holders — while 19 added to existing stakes and 6 trimmed.

The largest buyer was Affinity Asset Advisors, adding an estimated $10.4M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $2.09M sold.

  • 54 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q1 2026, up from 35 in Q4 2025.
  • Funds reported $157M of Eupraxia Pharmaceuticals stock for Q1 2026, up 51% quarter-over-quarter.
  • 22 funds opened new Eupraxia Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +19 holders.
  • The largest Eupraxia Pharmaceuticals buyer in Q1 2026 was Affinity Asset Advisors, an estimated $10.4M added.
  • The largest Eupraxia Pharmaceuticals seller in Q1 2026 was Arrowstreet Capital, an estimated $2.09M sold.

Based on aggregated 13F filings for Q1 2026.